Acinetobacter baumannii: A brief account of mechanisms of multidrug resistance and current and future therapeutic management

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 11, 2013, Pages 2602-2605

  Singh, Harmanjit ^a   Thangaraj, Pugazhenthan ^a   Chakrabarti, Amitava ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

A. baumannii; Colistin; CRAB; MDR Ab

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; POLYMYXIN B; POLYMYXIN DERIVATIVE; PORIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL OUTER MEMBRANE; BACTERICIDAL ACTIVITY; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; COMBINATION CHEMOTHERAPY; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; MEMBRANE BINDING; MENINGITIS; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMONIA; RECOMMENDED DRUG DOSE; REVIEW; SALVAGE THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 84887357663     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/6337.3626     Document Type: Review

References (42)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-582.
2. van Looveren M, Goossens H; ARPAC Steering Group. "Antimicrobial resistance of Acinetobacter spp. in Europe. " Clinical Microbiology and Infection. 2004; 10 (8):684-704.
3. Vila J, Marti S, Sanchez-Cespedes J. "Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. " Journal of Antimicrobial Chemotherapy. 2007;59(6):1210-5.
4. Houang ET, Sormunen RT, Lai L, Chan CY, Leong AS. Effect of desiccation on the ultrastructural appearances of Acinetobacter baumannii and Acinetobacter lwoffii. J. Clin. Pathol. 1998;51(10):786-8.
5. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. "Comparative genomics of multidrug resistance in Acinetobacter baumannii". PLOS Genet. 2006;2:e7.
6. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CS, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrobial Agents and Chemotherapy. 2006;50(12):4114-123.
7. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among gram negative bacilli as causes of infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007; 45:3352-359.
8. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(Suppl 2):49-56.
9. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2006; 43(Suppl 2):100-05.
10. Brown S, Amyes S. OXA b-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother. 2006; 57:1-3.
11. Thomson JM, Bonomo RA. The threat of antibiotic resistance in gram-negative pathogenic bacteria: beta-lactams in peril! Curr Opin Microbiol. 2005; 8:518-24.
12. Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob Agents Chemother. 2005; 49:1432-440.
13. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents. 2005; 25:11-25.
14. Guide to the Elimination of Multidrug-resistant Acinetobacter baumannii Transmission in Healthcare Settings. An APIC Guide. 2010. Available from http://www.apic.org/resource//b8b0b11f-1808-4615-890b-f652d116ba56/file/apic-ab-guide.pdf. Accessed on 2013 Apr 19.
15. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12: 826-36.
16. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries. 2009; 3(5):335-41.
17. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis. 1993; 167(2):448-51.
18. Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy. 2001; 21(2):142-48.
19. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M, Porath A, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect. 2003; 54(1):32-38.
20. Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents. 2009; 34(2):121-30.
21. Ikonomidis A, Pournaras S, Maniatis AN, Legakis NJ, Tsakris A. Discordance of meropenem versus imipenem activity against Acinetobacter baumannii. Int J Antimicrob Agents. 2006; 28(4):376-77.
22. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis. 2009; 49(2):291-98.
23. Katragkou A, Roilides E. Infections with Colistin baumannii Central Nervous System Multidrug-Resistant Acinetobacter J. Clin. Microbiol. 2005, 43(9):4916-917.
24. Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis, 2009; 9:26.
25. Hallal A, Cohn SM, Namias N, Habib F, Baracco G, Manning RJ, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect Larchmt, 2007; 8(1):73-82.
26. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother, 2004;38:1449-459.
27. Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9(4):245-55.
28. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004; 39(9):1267-284.
29. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother. 2004; 48:4479-481.
30. Ruzin A, Keeney D, Bradford PA. Ade ABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother. 2007; 59:1001-004.
31. Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, Anti-microbial Resistance, and Treatment Options. Clinical Infectious Diseases. 2008; 46: 1254-263.
32. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065-069.
33. Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy. 2007 Nov;27(11):1506-511.
34. Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacterbaumannii infections. J Antimicrob Chemother. 2006;58(3):697-700.
35. Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of ampicillin/sulbactam, doripenemand tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J of Antimicrob Chemother. 2013 [Epub ahead of print].
36. O'Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR, Ernst RK, et al. Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother. 2013;57(5):2103-108.
37. Toney JH. Metallo-beta-lactamase inhibitors: could they give old antibacterials new life? Curr. Opin. Investig. Drugs. 2003;4:115-16.
38. Boehr DD, Draker KA, Koteva K, Bains M, Hancock RE, Wright GD. Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes. Chem Biol. 2003;10(2):189-96.
39. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006;19(2):382-402.
40. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238-50.
41. Giacometti AO, Cirioni MS, Del Prete F, Barchiesi AM, Paggi E, Petrelli, et al. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother. 2000;46:807-10.
42. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67 (7):1607-615.